Interview with Paul Burke
Paul Burke, PhD Principal, Burke Bioventures LLC How did you become interested in the field of oligonucleotides? I first became interested in
Antisense oligonucleotide-mediated Dnm2 knockdown prevents and reverts myotubular myopathy in mice
Antisense oligonucleotide-mediated Dnm2 knockdown prevents and reverts myotubular myopathy in mice …………… Tasfaout H, Buono S, Guo S, Kretz C, Messaddeq N, Booten S, Greenlee S, Monia BP, Cowling BS, Laporte J. Nat Commun. 2017 Jun 7;8:15661. PubMed 00
Targeting DMPK with Antisense Oligonucleotide Improves Muscle Strength in Myotonic Dystrophy Type 1 Mice
Targeting DMPK with Antisense Oligonucleotide Improves Muscle Strength in Myotonic Dystrophy Type 1 Mice …………… Jauvin D, Chrétien J, Pandey SK, Martineau L, Revillod L, Bassez G, Lachon A, McLeod AR, Gourdon G, Wheeler TM, Thornton CA, Bennett CF, Puymirat J. Mol Ther Nucleic Acids. 2017 Jun 16;7:465-474. PubMed 00
Evaluation of Antisense Oligonucleotides Targeting ATXN3 in SCA3 Mouse Models
Evaluation of Antisense Oligonucleotides Targeting ATXN3 in SCA3 Mouse Models …………… Moore LR, Rajpal G, Dillingham IT, Qutob M, Blumenstein KG, Gattis D, Hung G, Kordasiewicz HB, Paulson HL, McLoughlin HS. Mol Ther Nucleic Acids. 2017 Jun 16;7:200-210. PubMed 00